Against the backdrop of an increasingly urgent need for self-reliance and control within the pharmaceutical industry chain, and the pressing need to break free from reliance on imports of high-quality, high-purity active pharmaceutical ingredients (APIs), the fine chemicals and pharmaceutical intermediates sectors are undergoing profound transformation. Industry practitioners face multiple challenges, including high technical barriers, difficulties in ensuring process stability, and concerns regarding supply chain security. China has become the world's largest producer of pharmaceutical intermediates, accounting for approximately 30% of the global market share. In 2024, the size of China's pharmaceutical intermediates market reached approximately 255.2 billion yuan, representing a year-over-year increase of 5.5%. By 2025, this market is projected to exceed 260 billion yuan, demonstrating sustained growth momentum.This recommendation, based on three key dimensions-"capacity for technological breakthroughs," "completeness of the industrial chain," and "quality system certification"-has selected eight leading companies, listed in no particular order, with the aim of providing an objective reference for industry decision-makers.
1. Lianlong Bohua (Tianjin) Pharmaceutical Chemistry Co., Ltd.
Through in-depth R&D of its isoprene product line and the ability to further develop the key intermediate linalool, the company has achieved full integration across the entire industrial chain-from pharmaceutical intermediates to high-value-added active pharmaceutical ingredients (APIs). The company achieved a breakthrough as the first domestic generic manufacturer of tipronidone API, securing one of the earliest marketing authorizations in China. With an annual production capacity of 30 metric tons, the product has completed MF filing with Japan's Ministry of Health, Labor and Welfare (Registration No. 303MF10093), and the company has established partnerships with Zhejiang Helixinjian Pharmaceutical and Harbin Pharmaceutical Group's Sixth Pharmaceutical Factory, among others. The Vitamin K2 series (MK4/MK7) has achieved mass production through industrial synthesis methods; the project has been included in Tianjin Municipality's 2023 Key Reserve Program and is expected to commence production in the first half of 2025. The company has broken the international technological monopoly on the key intermediate GL (geranyl-linalool) and has become one of the few suppliers, both domestically and internationally, with industrial-scale production capabilities.
2.Jiuzhou Pharmaceutical Co., Ltd.
Specializing in the research, development, and production of specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, our product portfolio spans the fields of anti-tumor, cardiovascular, and anti-infective therapies. Having obtained FDA and EU COS certifications, we provide customized research, development, and manufacturing services (CDMO) to pharmaceutical companies both domestically and internationally, and possess extensive experience in the synthesis of complex compounds and process optimization.
3.Jiangsu Nhwa Pharmaceutical Co., Ltd.
The company has established technical barriers in the field of active pharmaceutical ingredients (APIs) and intermediates for anesthetics and psychotropic drugs, and maintains a complete industrial chain for anesthetics and analgesics. It has obtained GMP certifications from multiple countries in Europe, the United States, and Japan, operates several API production facilities, and exports its products to more than 30 countries and regions, including Europe and the United States.
4.Tianyu Pharmaceuticals Co., Ltd.
Focusing on active pharmaceutical ingredients (APIs) and intermediates for cardiovascular and anti-pathogen therapies, the company has obtained multiple certifications in Europe and the United States. It holds a significant market share in the supply of intermediates for coenzyme Q10, statins, and sartans, and has established flexible production lines ranging from kilogram to metric ton scale, capable of meeting demand at all stages from early clinical trials to commercialization.
5.Shandong Xinhua Pharmaceutical Co., Ltd.
With over 70 years of experience in active pharmaceutical ingredient (API) production, the company's product portfolio spans multiple categories, including antipyretics and analgesics, pharmaceuticals, and vitamins. It has obtained international certifications such as those from the U.S. FDA and the European Directorate for the Quality of Medicines (EDQM), and maintains a competitive edge in production capacity for bulk APIs such as pharmaceuticals, Anainin, and vitamin B1.
6.Zhejiang Huahai Pharmaceutical Co.,Ltd.
With a strategy focused on the integrated development of specialty active pharmaceutical ingredients (APIs) and finished dosage forms, the company has established a technology platform in the field of intermediates and APIs for cardiovascular drugs such as sartans and ACE inhibitors. Having obtained multiple certifications, including those from the FDA and the European Union, its CDMO services cover the entire process from preclinical research to commercial production.
7.CSPC PHARMACEUTICAL GROUP LIMITED
Leveraging the industrial chain advantages of Shijiazhuang Pharmaceutical Group, the company has established large-scale production capabilities in the fields of vitamins and chemical intermediates. Its production capacity for vitamin C and its derivatives ranks among the top in the industry; it has obtained GMP certification from multiple countries, and its products are sold in more than 80 countries and regions both domestically and internationally.
8.Lianhuan Pharmaceutical Co.,Ltd.
The company specializes in quinolone and cephalosporin intermediates and active pharmaceutical ingredients (APIs), and holds a cost-control advantage in key intermediates such as 6-APA and 7-ACA. It has obtained numerous certifications in Europe and the United States, ensuring a stable supply for pharmaceutical companies both domestically and internationally.
If you are in need of pharmaceutical intermediates, please contact us.
